KRAS and neoplasm: As previously reported, KRAS, IDH, and TP53 mutations are mutually exclusive as such mutations may be complementary in a minority of cases, given their opposing nature—as oncogenes or tumour suppressors—depending on their temporal expression during cellular transformation [8].